Skip to main content

Table 1 Baseline clinical and laboratory characteristics of the study population according to the AIP quartiles

From: Prognostic impact of the atherogenic index of plasma in type 2 diabetes mellitus patients with acute coronary syndrome undergoing percutaneous coronary intervention

Variable

Q1

Q2

Q3

Q4

P value

n = 199

n = 200

n = 200

n = 199

Overall

Q2 vs. Q1 *

Q3 vs. Q1 *

Q3 vs. Q2 *

Q4 vs. Q1 *

Q4 vs. Q2 *

Q4 vs. Q3 *

Demographics

 Age (years)

63 ± 8

63 ± 10

61 ± 9

58 ± 12

< 0.001

0.750

0.051

0.498

< 0.001

< 0.001

0.007

 Male sex, n (%)

125 (62.8)

146 (73.0)

153 (76.5)

156 (78.4)

0.002

0.029

0.003

0.420

0.001

0.209

0.651

Clinical values (on admission)

 BMI (kg/m2)

25.3 ± 3.1

25.4 ± 2.8

26.1 ± 3.1

27.0 ± 3.5

< 0.001

0.997

0.081

0.129

< 0.001

< 0.001

0.028

 SBP (mm Hg)

133 ± 18

133 ± 17

130 ± 16

131 ± 16

0.116

–

–

–

–

–

–

 DBP (mm Hg)

75 ± 11

76 ± 10

75 ± 10

77 ± 11

0.203

–

–

–

–

–

–

Risk factors

 Smoking status

 Current smoking, n (%)

60 (30.2)

77 (38.5)

76 (38.0)

111 (55.8)

< 0.001

0.079

0.098

0.918

< 0.001

0.001

< 0.001

 Former smoking, n (%)

33 (16.6)

33 (16.5)

38 (19.0)

26 (13.1)

0.455

–

–

–

–

–

–

 Never smoking, n (%)

106 (53.3)

90 (45.0)

86 (43.0)

62 (31.2)

< 0.001

0.099

0.040

0.687

< 0.001

0.004

0.014

 Chronically daily drinking, n (%)

14 (7.0)

18 (9.0)

26 (13.0)

21 (10.6)

0.234

–

–

–

–

–

–

 Family history of CHD, n (%)

54 (27.1)

60 (30.0)

69 (34.5)

56 (28.1)

0.386

–

–

–

–

–

–

 Hypertension, n (%)

138 (69.3)

137 (68.5)

141 (70.5)

130 (65.3)

0.715

–

–

–

–

–

–

 Dyslipidaemia, n (%)

107 (53.8)

174 (87.0)

192 (96.0)

195 (98.0)

< 0.001

< 0.001

< 0.001

0.001

< 0.001

< 0.001

0.245

 Previous MI, n (%)

36 (18.1)

43 (21.5)

40 (20.0)

51 (25.6)

0.301

–

–

–

–

–

–

 Past PCI, n (%)

47 (23.6)

50 (25.0)

50 (25.0)

44 (22.1)

0.891

–

–

–

–

–

–

 Previous ischemic stroke or TIA, n (%)

13 (6.5)

13 (6.5)

17 (8.5)

8 (4.0)

0.338

–

–

–

–

–

–

 PAD, n (%)

27 (13.6)

29 (14.5)

31 (15.5)

33 (16.6)

0.853

–

–

–

–

–

–

 Cardiac failure, n (%)

12 (6.0)

13 (6.5)

23 (11.5)

19 (9.5)

0.156

–

–

–

–

–

–

 LVEF (%)

64 (60–67)

64 (60–68)

65 (60–68)

65 (59–68)

0.963

–

–

–

–

–

–

Clinical presentation

 UAP, n (%)

171 (85.9)

153 (76.5)

150 (75.0)

153 (76.9)

0.033

0.016

0.006

0.726

0.020

0.928

0.660

 NSTEMI, n (%)

19 (9.5)

28 (14.0)

28 (14.5)

25 (12.6)

0.493

–

–

–

–

–

–

 STEMI, n (%)

9 (4.5)

19 (9.5)

22 (11.0)

21 (10.6)

0.088

–

–

–

–

–

–

Laboratory measurements (fasting state)

 SCr (μmol/L)

66.5 (59.3–73.6)

69.2 (61.9–80.3)

70.3 (62.2–81.3)

71.5 (63.2–82.2)

< 0.001

0.041

0.023

1.000

< 0.001

0.966

1.000

 UA (μmol/L)

303.2 (271.7–347.2)

321.3 (279.6–373.0)

323.8 (282.5–386.0)

368.5 (307.0–410.3)

< 0.001

0.376

0.011

1.000

< 0.001

< 0.001

< 0.001

 TC (mmol/L)

3.90 ± 0.96

4.06 ± 1.01

4.10 ± 0.99

4.47 ± 1.03

< 0.001

0.341

0.179

0.984

< 0.001

< 0.001

0.002

 LDL-C (mmol/L)

2.23 ± 0.85

2.48 ± 0.84

2.48 ± 0.77

2.53 ± 0.76

0.001

0.011

0.012

1.000

0.001

0.926

0.916

 HDL-C (mmol/L)

1.23 ± 0.22

1.04 ± 0.17

0.95 ± 0.17

0.87 ± 0.14

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

 Triglycerides (mmol/L)

0.88 (0.72–1.00)

1.31 (1.18–1.48)

1.71 (1.51–1.99)

2.66 (2.25–3.38)

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

 FPG (mmol/L)

6.80 (6.12–8.23)

7.17 (6.32–8.25)

6.80 (5.91–7.88)

7.65 (6.61–8.49)

< 0.001

0.466

1.000

0.070

0.003

0.531

< 0.001

 Glycated haemoglobin (%)

7.0 (6.6–8.1)

7.3 (6.7–8.2)

7.2 (6.6–8.1)

7.3 (6.7–8.0)

0.409

–

–

–

–

–

–

 AIP

−0.1581 ± 0.1373

0.1029 ± 0.0482

0.2631 ± 0.0504

0.5272 ± 0.1773

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

  1. * P < 0.0083 is considered statistically significant for post hoc multiple comparisons of categorical variables between groups
  2. AIP Indicates atherogenic index of plasma; BMI Body mass index; SBP Systolic blood pressure; DBP Diastolic blood pressure; CHD Coronary heart disease; MI Myocardial infarction; PCI Percutaneous coronary intervention; TIA Transient ischemic attack; PAD Peripheral artery disease; LVEF Left ventricular ejection fraction; UAP Unstable angina pectoris; NSTEMI Non ST-segment elevation myocardial infarction; STEMI ST-segment elevation myocardial infarction; SCr Serum creatinine; UA Uric acid; TC Total cholesterol; LDL-C Low-density lipoprotein-cholesterol; HDL-C High-density lipoprotein-cholesterol; FPG Fasting plasma glucose